Last quarter (Q3 2023), Matinas BioPharma's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q3, Matinas BioPharma's net income was $-6.05M. See Matinas BioPharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 2.16M	$ 3.19M	$ 33.00K	$ 158.33K	$ 89.81K	$ 119.75K
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 2.16M	$ 3.19M	$ 33.00K	-	-	-
Operating Expense	$ 12.15M	$ 27.78M	$ 24.77M	$ 24.36M	$ 19.01M	$ 14.77M
Operating Income	$ -9.99M	$ -24.59M	$ -24.73M	$ -24.21M	$ -18.92M	$ -14.65M
Net Non Operating Interest Income Expense	-	$ -1.00K	$ 3.00K	-	-	-
Other Income Expense	$ -2.10M	$ -3.59M	$ -1.45M	$ 1.76M	$ 1.55M	$ 56.55K
Pretax Income	$ -7.90M	$ -21.00M	$ -23.28M	$ -22.45M	$ -17.37M	$ -14.59M
Tax Provision	-	-	-	-	$ 0.00	$ -506.92K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -7.90M	$ -21.00M	$ -23.68M	$ -23.24M	$ -18.30M	$ -14.99M
Basic EPS	$ -0.10	$ -0.10	$ -0.11	$ -0.12	$ -0.13	$ -0.15
Diluted EPS	$ -0.09	$ -0.10	$ -0.11	$ -0.12	$ -0.13	$ -0.15
Basic Average Shares	$ 868.61M	$ 216.81M	$ 210.18M	$ 196.89M	$ 145.20M	$ 98.10M
Diluted Average Shares	$ 651.79M	$ 216.81M	$ 210.18M	$ 196.89M	$ 145.20M	$ 98.10M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 12.15M	$ 27.78M	$ 24.77M	$ 24.36M	$ 19.01M	$ 14.77M
Net Income From Continuing And Discontinued Operation	$ -21.26M	$ -21.00M	$ -23.28M	$ -22.45M	$ -17.37M	$ -14.08M
Normalized Income	$ -4.78M	$ -16.59M	-	$ -23.52M	$ -18.38M	$ -14.08M
Interest Expense	-	-	-	-	-	-
EBIT	$ -7.90M	$ -21.00M	$ -23.29M	$ -24.21M	$ -18.92M	$ -14.65M
EBITDA	$ -7.29M	$ -19.89M	$ -22.25M	$ -23.43M	$ -18.14M	$ -14.43M

Currency in USD

Matinas BioPharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing